A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection

Journal of Infectious Diseases

Volumn 206, Issue 12, 2012, Pages 1844-1851

  Moss, Ronald B ^a   Hansen, Carrie ^a   Sanders, Rebecca L ^a   Hawley, Stephen ^a   Li, Tiejun ^a   Steigbigel, Roy T ^b  

^a NexBio Inc   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DAS 181; PLACEBO; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ABDOMINAL INFECTION; ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA B; MAJOR CLINICAL STUDY; MALE; PERINEAL INFECTION; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS SHEDDING;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PLACEBOS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84870226652     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis622     Document Type: Article

References (23)

1. Morens DM, Taubenberger JK, Fauci AS. The persistent legacy of the 1918 influenza virus. N Engl J Med 2009; 361:225-9.
2. Zimmer SM, Burke DS. Historical perspective - emergence of influenza A (H1N1) viruses. N Engl J Med 2009; 361:279-85.
3. White DB, Angus DC. Preparing for the sickest subjects with 2009 influenza A (H1N1) viruses. JAMA 2009; 302:1905-6.
4. Moss RB, Davey RT, Steigbigel RT, Fang F. Targeting pandemic influenza: A primer on influenza antivirals and drug resistance. J Antimicrob Chemother 2010; 65:1086-93.
5. US Department of Health and Human Services. Pandemic Influenza Plan. HHS. 2005. URL: Www.h.h.sgov/pandemicflu/plan/pdf/HHS PandemicinflunezaPlan.pdf
6. Ito T. Interspecies transmission and receptor recognition of influenza A viruses. Microbiol Immunol 2000; 44:423-30. (Pubitemid 30431762)
7. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:1470-9.
8. Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196:1493-9. (Pubitemid 351411986)
9. Triana-Baltzer GB, Gubareva LV, Klimov AI, et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS ONE 2009; 4:e7838.
10. Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 2009; 4:e7788.
11. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-24. (Pubitemid 30112215)
12. Kaiser L, Briones MS, Hayden FG. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol 1999; 14:191-7.
13. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337: 874-80. (Pubitemid 27408569)
14. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in subjects with mild pandemic 2009 influenza A H1N1: Opportunistic retrospective study of medical charts in China. BMJ 2010; 341.
15. Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: A significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis 2003; 35:52-8. (Pubitemid 36336368)
16. US Food and Drug Administration. Relenza Medical Review. FDA. 1998. URL: Www.accessdata.fda.gov/drgsatfda-docs/label/1999/2103 61bl.pdf
17. US Center for Disease Control and Prevention. Rapid Diagnostic Testing for Influenza. CDC. 2012. URL: Http://www.cdc.gov/flu/professionals/diagnosis/ rapidlab.htm.
18. Sambol AR, Abdalhamid B, Lyden ER, Aden TA, Noel RK, Hinrichs SH. Use of rapid influenza diagnostic tests under field conditions as a screening tool during an outbreak of the 2009 novel influenza virus: Practical considerations. J Clin Virol 2010; 47:229-33.
19. Stevenson HL, Loeffelholz MJ. Poor positive accuracy of QuickVue rapid antigen tests during the influenza A (H1N1) 2009 pandemic. Clin Microbiol 2010; 48:3729-31.
20. Larson JL, Kang SK, Choi BI, et al. A safety evaluation of DAS181, a sialidase fusion protein, in rodents. Toxicol Sci 2011.
21. Stockert RJ. The asialoglycoprotein receptor: Relationships between structure, function, and expression. Physiol Rev 1995; 75:591-609.
22. Blom E, Ali MM, Mortensen B, Huseby NE. Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates. Clin Chim Acta 1998; 270: 125-37. (Pubitemid 28095685)
23. Berns K, Casadevall A, Cohen ML, et al. Public health and viosecurity. Adaptations of avian flu virus are a cause for concern. Science 2012; 335:660-1.